Disease · MONDO_0019100
neuromyelitis optica
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. neuromyelitis optica. Diseases, record MONDO_0019100. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0019100
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
- Devic disease, Devic syndrome, Devic's disease, Devic's syndrome, Neuromyelitis Optica Spectrum Disorder
- Open Targets
- Highest stage of its drugs
- Approval, for 3 of its 50 drugs, from EMA Human Drugs, FDA, PMDA and TTD
- Open Targets
Drugs50
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| ECULIZUMAB | CHEMBL1201828 | Antibody | Approval | TTD | 10 | 9 | 9 | Drugs and targets |
| INEBILIZUMAB | CHEMBL2109334 | Antibody | Approval | EMA Human Drugs, FDA, PMDA and TTD | 12 | 6 | 6 | Drugs and targets |
| SATRALIZUMAB | CHEMBL3833307 | Antibody | Approval | EMA Human Drugs, FDA, PMDA and TTD | 12 | 6 | 6 | Drugs and targets |
| METHYLPREDNISOLONE | CHEMBL650 | Small molecule | Phase 3 | ClinicalTrials.gov | 10 | 10 | 8 | Drugs and targets |
| RITUXIMAB | CHEMBL1201576 | Antibody | Phase 3 | ClinicalTrials.gov | 6 | 6 | 6 | Drugs and targets |
| AZATHIOPRINE | CHEMBL1542 | Small molecule | Phase 3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| RAVULIZUMAB | CHEMBL3989986 | Antibody | Phase 3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| HUMAN IMMUNOGLOBULIN G | CHEMBL1201599 | Phase 3 | ClinicalTrials.gov | 3 | 3 | 0 | Drugs and targets | |
| PREDNISONE | CHEMBL635 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 1 | Drugs and targets |
| BETAMETHASONE | CHEMBL632 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 0 | Drugs and targets |
1 to 10 of 50
See all 50 drugsTargets64
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| NR3C1 | Glucocorticoid receptor | 8 | Glucocorticoid receptor agonist | Phase 3 | https://conductscience.org/library/genes/2908 | Drugs and targets |
| MS4A1 | B-lymphocyte antigen CD20 | 4 | B-lymphocyte antigen CD20 binding agent | Phase 3 | https://conductscience.org/library/genes/931 | Drugs and targets |
| CSF3R | Granulocyte colony-stimulating factor receptor | 3 | Granulocyte colony stimulating factor receptor agonist | Phase 2/3 | https://conductscience.org/library/genes/1441 | Drugs and targets |
| EPOR | Erythropoietin receptor | 3 | Erythropoietin receptor agonist | Unknown | https://conductscience.org/library/genes/2057 | Drugs and targets |
| BTK | Tyrosine-protein kinase BTK | 2 | Tyrosine-protein kinase BTK inhibitor | Phase 2 | https://conductscience.org/library/genes/695 | Drugs and targets |
| C5 | Complement C5 | 2 | Complement C5 inhibitor | Approval | https://conductscience.org/library/genes/727 | Drugs and targets |
| FCGRT | IgG receptor FcRn large subunit p51 | 2 | IgG receptor FcRn large subunit p51 antagonist; IgG receptor FcRn large subunit p51 inhibitor | Phase 2 | https://conductscience.org/library/genes/2217 | Drugs and targets |
| IL6R | IL6Ralpha/GP130 | 2 | IL6Ralpha/GP130 antagonist; Interleukin-6 receptor alpha subunit inhibitor | Approval | https://conductscience.org/library/genes/3570 | Drugs and targets |
| JAK1 | Tyrosine-protein kinase JAK1 | 2 | Tyrosine-protein kinase JAK1 inhibitor | Phase 1/2 | https://conductscience.org/library/genes/3716 | Drugs and targets |
| JAK2 | Tyrosine-protein kinase JAK2 | 2 | Tyrosine-protein kinase JAK2 inhibitor | Phase 1/2 | https://conductscience.org/library/genes/3717 | Drugs and targets |
1 to 10 of 64
See all 64 targetsTrials55
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 4 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01892345 | A Randomized Controlled Trial of Eculizumab in AQP4 Antibody-positive Participants With NMO (PREVENT Study) | Phase 3 | 143 | 2019-06-26 | Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder | ECULIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02003144 | An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients | Phase 3 | 119 | 2022-08-23 | Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder | ECULIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT04660539 | A Study to Evaluate the Safety and Efficacy of Satralizumab in Participants With Neuromyelitis Optica Spectrum Disorder (NMOSD) | Phase 3 | 119 | 2024-12-27 | Neuromyelitis Optica Spectrum Disorder | AZATHIOPRINE, MYCOPHENOLATE MOFETIL, SATRALIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02073279 | Efficacy and Safety Study of Satralizumab (SA237) as Monotherapy to Treat Participants With Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD) | Phase 3 | 95 | 2020-12-31 | Neuromyelitis Optica (NMO), NMO Spectrum Disorder (NMOSD) | SATRALIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT03002038 | Comparison of Clinical Effects of Azathioprine and Rituximab NMO-SD Patients | Phase 2/3 | 86 | 2020-09-30 | Neuromyelitis Optica Spectrum Disorder | AZATHIOPRINE, RITUXIMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02028884 | Efficacy and Safety Study of Satralizumab (SA237) as Add-on Therapy to Treat Participants With Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD) | Phase 3 | 85 | 2020-12-31 | Neuromyelitis Optica (NMO), NMO Spectrum Disorder (NMOSD) | SATRALIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT04201262 | An Efficacy and Safety Study of Ravulizumab in Adult Participants With NMOSD | Phase 3 | 58 | 2023-08-09 | Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder | RAVULIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02865018 | Neuromyelitis Optica (NMO) & Cetirizine | Phase 1/2 | 16 | 2023-06-07 | Neuromyelitis Optica | CETIRIZINE | Its record names the disease | ClinicalTrials.gov |
| NCT00904826 | An Open Label Study of the Effects of Eculizumab in Neuromyelitis Optica | Phase 1/2 | 14 | 2013-11-04 | Neuromyelitis Optica, Devic's Disease | ECULIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT00787722 | Hematopoietic Stem Cell Transplant in Devic's Disease | Phase 1/2 | 13 | 2020-02-28 | Devic's Disease | CYCLOPHOSPHAMIDE, RITUXIMAB | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 55
See all 55 trialsComparisons in its trials14
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Eculizumab vs Placebo: Participants With An Adjudicated On-trial Relapse | 3 of 96 | 20 of 47 | 143 | NCT01892345 | Trial comparisons |
| Eculizumab vs Placebo: deaths from any cause | 1 of 96 | 0 of 47 | 143 | NCT01892345 | Trial comparisons |
| Eculizumab vs Placebo: serious adverse events | 30 of 96 | 26 of 47 | 143 | NCT01892345 | Trial comparisons |
| Eculizumab/Eculizumab vs Placebo/Eculizumab: Number of Participants With An On-trial Relapse as Determined by The Treating Physician | 8 of 78 | 5 of 41 | 119 | NCT02003144 | Trial comparisons |
| Ravulizumab vs Placebo (ECU-NMO-301): Number of Participants With an Adjudicated On-trial Relapse in the Primary Treatment Period | 0 of 58 | 20 of 47 | 105 | NCT04201262 | Trial comparisons |
| Satralizumab, Then Satralizumab vs Placebo, Then Satralizumab: Number of Participants With Non-Serious Adverse Events of Special Interest in the DB Period | 0 of 63 | 0 of 32 | 95 | NCT02073279 | Trial comparisons |
| Satralizumab, Then Satralizumab vs Placebo, Then Satralizumab: Number of Participants With at Least One Adverse Event in the DB Period | 58 of 63 | 24 of 32 | 95 | NCT02073279 | Trial comparisons |
| Satralizumab, Then Satralizumab vs Placebo, Then Satralizumab: Number of Participants With at Least One Serious Adverse Event in the DB Period | 12 of 63 | 5 of 32 | 95 | NCT02073279 | Trial comparisons |
| Azathioprine vs Rituximab: Number of Participants With Adverse Drug Reactions | 3 of 46 | 4 of 40 | 86 | NCT03002038 | Trial comparisons |
| Azathioprine vs Rituximab: deaths from any cause | 0 of 46 | 0 of 40 | 86 | NCT03002038 | Trial comparisons |
1 to 10 of 14
See all 14 comparisons in its trialsPapers from its trials23
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0019100
GET https://conductscience.org/api/diseases/v1/MONDO_0019100/drugs?page=2